Video

GenesisCare administers novel diagnostic agent Pylarify to first US patient

This video features commentary from Leonard Bitterman, the first patient in the United States to receive Pylarify (piflufolastat F 18), a novel radioactive diagnostic agent indicated for PSMA-PET imaging of lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy and men with suspected recurrence based on an elevated PSA level. Brief commentary is also provided by Kishore K. Dass, MD, a radiation oncologist at GenesisCare in Boca Raton, Florida, where Bitterman received the treatment.

Related Videos
Dr. Shore on next steps with PARP inhibitors in prostate cancer
Dr. Shore on next steps with PARP inhibitors in prostate cancer
Typical Presentations of Metastatic Prostate Cancer and Risk of Disease Progression
Typical Presentations of Metastatic Prostate Cancer and Risk of Disease Progression
Incidence of Advanced Prostate Cancer
Incidence of Advanced Prostate Cancer
Dr. Koontz gives an overview of ASTRO discussion on new RTOG-0815 data
Dr. Koontz gives an overview of ASTRO discussion on new RTOG-0815 data
Study investigates management strategies for intermediate to high-risk prostate cancer
Study investigates management strategies for intermediate to high-risk prostate cancer
Dr. Koontz on study of dose-escalated RT plus androgen suppression in prostate cancer
Dr. Koontz on study of dose-escalated RT plus androgen suppression in prostate cancer
GenesisCare physicians discuss PSMA-PET imaging agent Pylarify
GenesisCare physicians discuss PSMA-PET imaging agent Pylarify
Dr. Shore on US launch of PSMA PET imaging agent piflufolastat F 18 for prostate cancer
Dr. Shore on US launch of PSMA PET imaging agent piflufolastat F 18 for prostate cancer
Related Content
FDA grants Fast Track Designation to RAG-01 in NMIBC
May 21st 2024

FDA grants Fast Track Designation to RAG-01 in NMIBC

Hannah Clarke Jason M. Broderick
RAG-01 is an saRNA therapy that is delivered via intravesical instillation and is designed to target and activate p21, a tumor suppressor gene.
Novel small activating RNA therapy explored in NMIBC
April 12th 2024

Novel small activating RNA therapy explored in NMIBC

Jason M. Broderick
The study is exploring the small activating RNA therapy RAG-01 in patients with BCG-unresponsive non–muscle-invasive bladder cancer.
Phase 3 study launches exploring TLX591 in mCRPC
November 13th 2023

Phase 3 study launches exploring TLX591 in mCRPC

Hannah Clarke
The ProstACT GLOBAL study is investigating second-line TLX591 in combination with the current standard of care (SOC) vs SOC alone in patients with mCRPC who have progressed on a novel androgen axis drug.
Radio–antibody drug conjugate elicits antitumor activity in PSMA-positive mCRPC
October 19th 2023

Radio–antibody drug conjugate elicits antitumor activity in PSMA-positive mCRPC

Jason M. Broderick
Treatment with TLX591 resulted in a PSA reduction in nearly two-thirds of evaluable patients with PSMA-expressing metastatic castration-resistant prostate cancer.
Study launches of novel PSMA-targeting antibody in biochemically recurrent prostate cancer
September 27th 2022

Study launches of novel PSMA-targeting antibody in biochemically recurrent prostate cancer

Jason M. Broderick
The phase 2 ProstACT TARGET study is exploring TLX591 (177Lu-DOTA-rosopatamab) in combination with external beam radiation therapy.
GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial
February 11th 2022

GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial

GenesisCare
For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.
© 2025 MJH Life Sciences

All rights reserved.